Institute of Immunology University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Institute of Immunology University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Biochem Pharmacol. 2021 May;187:114394. doi: 10.1016/j.bcp.2020.114394. Epub 2021 Jan 1.
Nanobodies (VHHs) are the single variable immunoglobulin domains of heavy chain antibodies (hcAbs) that naturally occur in alpacas and other camelids. The two variable domains of conventional antibodies typically interact via a hydrophobic interface. In contrast, the corresponding surface area of nanobodies is hydrophilic, rendering these single immunoglobulin domains highly soluble, robust to harsh environments, and exceptionally easy to format into bispecific reagents. In homage to Geoffrey Burnstock, the pioneer of purinergic signaling, we provide a brief history of nanobody-mediated modulation of purinergic signaling, using our nanobodies targeting P2X7 and the NAD-metabolizing ecto-enzymes CD38 and ARTC2.2 as examples.
纳米抗体（VHH）是重链抗体（hcAb）的单可变免疫球蛋白结构域，天然存在于羊驼和其他骆驼科动物中。传统抗体的两个可变结构域通常通过疏水界面相互作用。相比之下，纳米抗体的相应表面积是亲水的，这使得这些单免疫球蛋白结构域具有高度的可溶性、对恶劣环境的耐受性以及非常容易形成双特异性试剂。为了向嘌呤能信号的先驱 Geoffrey Burnstock 致敬，我们提供了纳米抗体介导的嘌呤能信号调节的简要历史，使用我们针对 P2X7 以及 NAD 代谢的胞外酶 CD38 和 ARTC2.2 的纳米抗体作为示例。
